Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI

NCT05845749 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

6

Enrollment

OTHER

Sponsor class

Conditions

MPS IVA
MPS VI

Interventions

DRUG: Vosoritide Injection [Voxzogo]

Sponsor

University of California, San Francisco